Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Revenue

Price Targets

# of Analysts

Consensus Recommendation

EBITDA

EBIT

Free Cash Flow

FFO / Share

AFFO / Share

NAV / Share

Book Value / Share

CapEx

Estimates	Dec '23 (A)	Dec '24 (A)	Dec '25 (E)
Mean	CN¥23,440.09	CN¥27,123.78	CN¥33,098.09
Median	CN¥23,424.38	CN¥27,144.50	CN¥33,224.68
Actual	CN¥22,819.78	CN¥27,984.61	—
High	CN¥24,601.00	CN¥28,222.05	CN¥34,509.00
Low	CN¥22,647.00	CN¥26,028.00	CN¥31,435.26
Standard Deviation	CN¥473.83	CN¥436.12	CN¥934.58
# of Estimates	22	24	24